Journal of Hematology & Oncology | |
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | |
Cheolwon Suh1,12  Won Seog Kim9  Seok Jin Kim9  Sun Kyung Baek8  Jae-Heon Jeong8  Jae-sook Ahn3  HyeonSeok Eom7  Hwe-Won Lee7  Won-Sik Lee1,13  Joung-Soon Jang1  Eun Kyung Park1  Suee Lee4  Sung Yong Oh4  Joon Seong Park1,14  Seong Hyun Jeong1,14  Young Rok Do1,11  Yong Park1,15  Yeung-Chul Mun6  Ho-Jin Shin2  Dok Hyun Yoon1,12  Yoo Hong Min5  Jin Seok Kim1,10  Yu Ri Kim5  | |
[1] Chung-Ang University Hospital, Seoul, Korea;Pusan National University Hospital, Busan, Korea;Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Korea;Dong-A University College of Medicine, Busan, Korea;Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea;Ewha Womans University School of Medicine, Seoul, Korea;National Cancer Center, Goyang, Korea;Kyung Hee University Medical Center, Seoul, Korea;Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;Department of Internal Medicine, Division of Hematology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea;Keimyung University School of Medicine, Daegu, Korea;Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;Busan Paik Hospital, Inje University College of Medicine, Busan, Korea;Ajou University School of Medicine, Suwon, Korea;Korea University College of Medicine, Seoul, Korea | |
关键词: R-CHOP; Prognostic factor; Diffuse large B-cell lymphoma; Primary adrenal lymphoma; | |
Others : 822225 DOI : 10.1186/1756-8722-5-49 |
|
received in 2012-07-20, accepted in 2012-08-07, 发布年份 2012 | |
【 摘 要 】
Background
The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.
Methods
Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed.
Results
Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001).
Conclusions
Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.
【 授权许可】
2012 Kim et al; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20140712094949224.pdf | 690KB | download | |
Figure 4. | 21KB | Image | download |
Figure 3. | 18KB | Image | download |
Figure 2. | 28KB | Image | download |
Figure 1. | 41KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
【 参考文献 】
- [1]Baar J, Burkes RL, Bell R, Blackstein ME, Fernandes B, Langer F: Primary non-Hodgkin’s lymphoma of bone. A clinicopathologic study. Cancer 1994, 73:1194-1199.
- [2]Kumar R, Xiu Y, Mavi A, El-Haddad G, Zhuang H, Alavi A: FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 2005, 30:222-230.
- [3]Singh D, Kumar L, Sharma A, Vijayaraghavan M, Thulkar S, Tandon N: Adrenal involvement in non-Hodgkin’s lymphoma: four cases and review of literature. Leuk Lymphoma 2004, 45:789-794.
- [4]Horiguchi K, Hashimoto K, Hashizume M, Masuo T, Suto M, Okajo J, Handa H, Kaneko Y, Yokoo H, Sasaki A, et al.: Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure. Internal medicine (Tokyo, Japan) 2010, 49:2241-2246.
- [5]Kim KM, Yoon DH, Lee SG, Lim SN, Sug LJ, Huh J, Suh C: A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. J Korean Med Sci 2009, 24:525-528.
- [6]Grigg AP, Connors JM: Primary adrenal lymphoma. Clin Lymphoma 2003, 4:154-160.
- [7]Hsu CW, Ho CL, Sheu WH, Harn HJ, Chao TY: Adrenal insufficiency caused by primary aggressive non-Hodgkin’s lymphoma of bilateral adrenal glands: report of a case and literature review. Ann Hematol 1999, 78:151-154.
- [8]Yang Y, Li Q, Pan Y: Bilateral primary adrenal lymphoma. Br J Haematol 2010, 150:250–250.
- [9]Yamamoto E, Ozaki N, Nakagawa M, Kimoto M: Primary bilateral adrenal lymphoma associated with idiopathic thrombocytopenic purpura. Leuk Lymphoma 1999, 35:403-408.
- [10]Mermershtain W, Liel Y, Zirkin HJ, Lupu L, Lantsberg S, Cohen Y: Primary bilateral adrenal lymphoma relapsing as a solid cerebral mass after complete clinical remission: a case report. Am J Clin Oncol 2001, 24:583-585.
- [11]Lim KH, Chiou TY, Lin CJ, Hsieh RK: Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis. Medical oncology (Northwood, London, England) 2008, 25:107-109.
- [12]Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM: Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003, 14:131-139.
- [13]Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, et al.: Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21:20-27.
- [14]Edge SBB DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC cancer staging manual. 7th edition. Springer; 2010. http://openlink.ymlib.yonsei.ac.kr:8000/link.cgi?url=http://online.statref.com/document.aspx?FxId=73&DocID=1&grpalias=Yonsei webcite. ISBN : 0387884424 9780387884424
- [15]Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35–2000. An 82-year-old woman with bilateral adrenal masses and low-grade fever N Engl J Med 2000, 343:1477-1483.
- [16]Levy NT, Young WF, Habermann TM, Strickler JG, Carney JA, Stanson AW: Adrenal insufficiency as a manifestation of disseminated non-Hodgkin’s lymphoma. Mayo Clin Proc 1997, 72:818-822.
- [17]Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005, 23:4117-4126.
- [18]Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, et al.: Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011, 12:460-468.
- [19]Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, et al.: Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008, 19:233-241.
- [20]Rohatiner A, d’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M, et al.: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994, 5:397-400.
- [21]Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, et al.: Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000, 11:685-690.
- [22]Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N: Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007, 18:149-157.
- [23]Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI: Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27:114-119.
- [24]Mozos A, Ye H, Chuang WY, Chu JS, Huang WT, Chen HK, Hsu YH, Bacon CM, Du MQ, Campo E, Chuang SS: Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009, 22:1210-1217.
- [25]Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009, 115:243-250.
- [26]Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
- [27]Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989, 7:1630-1636.
- [28]A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project N Engl J Med 1993, 329:987-994.
- [29]Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al.: Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999, 17:1244.